Cargando…

Methamphetamine‐related cardiovascular diseases

AIMS: Abuse of crystal methamphetamine (MA) poses a growing problem for health services worldwide. This review summarizes the current literature on the effects of MA on the cardiovascular system. METHODS AND RESULTS: This article is a presentation of a case report and review of the current literatur...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarzbach, Valentin, Lenk, Karsten, Laufs, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160483/
https://www.ncbi.nlm.nih.gov/pubmed/31950731
http://dx.doi.org/10.1002/ehf2.12572
_version_ 1783522763243257856
author Schwarzbach, Valentin
Lenk, Karsten
Laufs, Ulrich
author_facet Schwarzbach, Valentin
Lenk, Karsten
Laufs, Ulrich
author_sort Schwarzbach, Valentin
collection PubMed
description AIMS: Abuse of crystal methamphetamine (MA) poses a growing problem for health services worldwide. This review summarizes the current literature on the effects of MA on the cardiovascular system. METHODS AND RESULTS: This article is a presentation of a case report and review of the current literature. In Europe, especially the eastern countries and the eastern states of Germany are affected. MA increases the concentration of catecholamines in the synaptic gap leading to euphoria, alertness, and hunger suppression as well as psychiatric and gastrointestinal complications. MA consumption is associated with hypertension, acute and chronic myocardial toxicity, stroke, coronary artery disease, and sudden cardiac death. Although many aspects of the underlying pathophysiology remain unknown, catecholamine‐mediated pathologies appear to play an important role. The duration of MA consumption is the most important determinant for the prognosis. CONCLUSIONS: Awareness is needed as cardiac complications are important causes of morbidity and mortality in patients with MA consumption. Drug abstinence is the mainstay of therapy, cardiac and other complications should be treated according to the respective guidelines. Incompliance to therapy and frequent relapses are the main challenges for successful treatment. Further research is required to improve the understanding of this rapidly increasing cardiomyopathy.
format Online
Article
Text
id pubmed-7160483
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71604832020-04-20 Methamphetamine‐related cardiovascular diseases Schwarzbach, Valentin Lenk, Karsten Laufs, Ulrich ESC Heart Fail Reviews AIMS: Abuse of crystal methamphetamine (MA) poses a growing problem for health services worldwide. This review summarizes the current literature on the effects of MA on the cardiovascular system. METHODS AND RESULTS: This article is a presentation of a case report and review of the current literature. In Europe, especially the eastern countries and the eastern states of Germany are affected. MA increases the concentration of catecholamines in the synaptic gap leading to euphoria, alertness, and hunger suppression as well as psychiatric and gastrointestinal complications. MA consumption is associated with hypertension, acute and chronic myocardial toxicity, stroke, coronary artery disease, and sudden cardiac death. Although many aspects of the underlying pathophysiology remain unknown, catecholamine‐mediated pathologies appear to play an important role. The duration of MA consumption is the most important determinant for the prognosis. CONCLUSIONS: Awareness is needed as cardiac complications are important causes of morbidity and mortality in patients with MA consumption. Drug abstinence is the mainstay of therapy, cardiac and other complications should be treated according to the respective guidelines. Incompliance to therapy and frequent relapses are the main challenges for successful treatment. Further research is required to improve the understanding of this rapidly increasing cardiomyopathy. John Wiley and Sons Inc. 2020-01-17 /pmc/articles/PMC7160483/ /pubmed/31950731 http://dx.doi.org/10.1002/ehf2.12572 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Reviews
Schwarzbach, Valentin
Lenk, Karsten
Laufs, Ulrich
Methamphetamine‐related cardiovascular diseases
title Methamphetamine‐related cardiovascular diseases
title_full Methamphetamine‐related cardiovascular diseases
title_fullStr Methamphetamine‐related cardiovascular diseases
title_full_unstemmed Methamphetamine‐related cardiovascular diseases
title_short Methamphetamine‐related cardiovascular diseases
title_sort methamphetamine‐related cardiovascular diseases
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160483/
https://www.ncbi.nlm.nih.gov/pubmed/31950731
http://dx.doi.org/10.1002/ehf2.12572
work_keys_str_mv AT schwarzbachvalentin methamphetaminerelatedcardiovasculardiseases
AT lenkkarsten methamphetaminerelatedcardiovasculardiseases
AT laufsulrich methamphetaminerelatedcardiovasculardiseases